Hemophilia - Epidemiology Market Size, Share, Emerging Trends,
Analysis and Forecasts-2026
“Hemophilia is an X-linked hereditary bleeding disorder characterized by
impaired blood coagulation as a result of deficiencies in the production or
function of coagulation factor VIII (FVIII) in hemophilia A, or factor IX (FIX)
in hemophilia B.”
Summary
Hemophilia is an X-linked hereditary bleeding disorder characterized by impaired blood coagulation as a result
of deficiencies in the production or function of coagulation factor VIII (FVIII) in hemophilia A, or factor IX (FIX)
in hemophilia B. Because of the deficiency of coagulation factor, hemophilia patients have a tendency for
bleeding in joints, muscles, soft tissues, and within mucous membranes, which can be either spontaneous or
due to internal or external trauma, depending on the severity of the disease.
In the 7MM, epidemiologists forecast an increase in the diagnosed prevalent cases of hemophilia A and
hemophilia B, from 51,627 diagnosed prevalent cases in 2016 to 52,566 diagnosed prevalent cases in 2026,
with an Annual Growth Rate (AGR) of 0.18% during the forecast period. The US will have the highest number
of diagnosed prevalent cases of hemophilia A and hemophilia B among the 7MM throughout the forecast
period, while Spain will have the lowest.
Browse Detail Report With TOC @
http://www.hexareports.com/report/epicast-report-hemophilia-epidemiology-forecast-to-2026
Follow Us: